0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

1
Articles   |    
Analysis of 94 Candidate Genes and 12 Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia
Tiffany A. Greenwood, Ph.D.; Laura C. Lazzeroni, Ph.D.; Sarah S. Murray, Ph.D.; Kristin S. Cadenhead, M.D.; Monica E. Calkins, Ph.D.; Dorcas J. Dobie, M.D.; Michael F. Green, Ph.D.; Raquel E. Gur, M.D., Ph.D.; Ruben C. Gur, Ph.D.; Gary Hardiman, Ph.D.; John R. Kelsoe, M.D.; Sherry Leonard, Ph.D.; Gregory A. Light, Ph.D.; Keith H. Nuechterlein, Ph.D.; Ann Olincy, M.D.; Allen D. Radant, M.D.; Nicholas J. Schork, Ph.D.; Larry J. Seidman, Ph.D.; Larry J. Siever, M.D.; Jeremy M. Silverman, Ph.D.; William S. Stone, Ph.D.; Neal R. Swerdlow, M.D., Ph.D.; Debby W. Tsuang, M.D., M.Sc.; Ming T. Tsuang, M.D., Ph.D., D.Sc.; Bruce I. Turetsky, M.D.; Robert Freedman, M.D.; David L. Braff, M.D.
Am J Psychiatry 2011;168:930-946. doi:10.1176/appi.ajp.2011.10050723
View Author and Article Information

Received May 17, 2010; revisions received Oct. 12 and Dec. 20, 2010; accepted Feb. 4, 2011.

Presented in part at the 57th annual meeting of the American Society of Human Genetics, San Diego, Oct. 23–27, 2007; the 46th annual meeting of the American College of Neuropsychopharmacology, Boca Raton, Fla., Dec. 9–12, 2007; the 63rd annual meeting of the Society for Biological Psychiatry, Washington, D.C., April 30 to May 3, 2008; and the XVIth World Congress on Psychiatric Genetics, Osaka, Japan, Oct. 11–15, 2008.

Dr. Greenwood has received unrelated support for consulting services from INFOTECH Soft. Dr. Freedman has a patent through the VA on DNA sequences in CHRNA7. Dr. Green has been a consultant for Abbott, Cypress, Dainippon Sumitomo, Lundbeck, Otsuka, Sanofi-Aventis, Takeda, and Teva, and he has been a speaker for Janssen Cilag, Otsuka, and Sunovion. Dr. Raquel Gur has received unrelated research support from AstraZeneca and Pfizer. Dr. Ruben Gur is a consultant to Johnson and Johnson and has received investigator-initiated grants from AstraZeneca, Merck, and Pfizer. Dr. Kelsoe is a consultant for AstraZeneca and Psynomics and is on a speakers bureau for Merck. Dr. Light has received unrelated support for consulting services from Allergan, Memory, and Roche. Dr. Nuechterlein reports an investigator-initiated research grant from Ortho-McNeil Janssen Scientific Affairs and consultation to Merck and Wyeth. Dr. Olincy has received unrelated research support from Lundbeck. Dr. Turetsky has received unrelated research support from AstraZeneca and Pfizer and is a consultant to Roche. The other authors report no financial relationships with commercial interests.

This study was supported by NIMH grants R01-MH-065571, R01-MH-065588, R01-MH-065562, R01-MH-065707, R01-MH-065554, R01-MH-065578, R01-MH-065558, R01-MH-86135, P50-MH-086383 (Dr. Freedman), and K01-MH-087889 (Dr. Greenwood); by grant DK-063491 from the National Institute of Diabetes and Digestive and Kidney Diseases (Dr. Hardiman); by the Department of Veterans Affairs, Veterans Integrated Service Network (VISN) 22, Mental Illness Research, Education, and Clinical Center (Dr. Braff); by a NARSAD Distinguished Investigator Award (Dr. Braff); and by additional salary support of Dr. Lazzeroni from VA Cooperative Studies Program study 478 and the Department of Veterans Affairs VISN-21 Mental Illness Research, Education, and Clinical Center.

From the Department of Psychiatry, the Department of Medicine, and the Biomedical Genomics Laboratory, University of California at San Diego, La Jolla; the San Diego VA Healthcare System; Scripps Genomic Medicine and the Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif.; the Department of Psychiatry and Behavioral Sciences and the Department of Pediatrics, Stanford University, Stanford, Calif.; the Department of Psychiatry, University of Pennsylvania, Philadelphia; the Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle; the VA Puget Sound Health Care System, Seattle; the Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine, UCLA; the Department of Psychiatry, University of Colorado Health Sciences Center, Denver; the Department of Psychiatry, Harvard Medical School and the Harvard Institute of Psychiatric Epidemiology and Genetics, Boston; the Mental Health Center Public Psychiatry Division, Beth Israel Deaconess Medical Center, Boston; the Department of Psychiatry, Mount Sinai School of Medicine, New York; and the James J. Peters VA Medical Center, New York.

Address correspondence and reprint requests to Dr. Braff, Department of Psychiatry, University of California at San Diego, Mail Code 0804, 9500 Gilman Dr., La Jolla, CA 92093-0804; dbraff@ucsd.edu (e-mail).

Received May 17, 2010; Revised October 12, 2010; Revised December 20, 2010; Accepted February 4, 2011.

Copyright © American Psychiatric Association

Objective:  The authors used a custom array of 1,536 single-nucleotide polymorphisms (SNPs) to interrogate 94 functionally relevant candidate genes for schizophrenia and identify associations with 12 heritable neurophysiological and neurocognitive endophenotypes in data collected by the Consortium on the Genetics of Schizophrenia.

Method:  Variance-component association analyses of 534 genotyped subjects from 130 families were conducted by using Merlin software. A novel bootstrap total significance test was also developed to overcome the limitations of existing genomic multiple testing methods and robustly demonstrate significant associations in the context of complex family data and possible population stratification effects.

Results:  Associations with endophenotypes were observed for 46 genes of potential functional significance, with three SNPs at p<10–4, 27 SNPs at p<10–3, and 147 SNPs at p<0.01. The bootstrap analyses confirmed that the 47 SNP-endophenotype combinations with the strongest evidence of association significantly exceeded that expected by chance alone, with 93% of these findings expected to be true. Many of the genes interact on a molecular level, and eight genes (e.g., NRG1 and ERBB4) displayed evidence for pleiotropy, revealing associations with four or more endophenotypes. The results collectively support a strong role for genes related to glutamate signaling in mediating schizophrenia susceptibility.

Conclusions:  This study supports use of relevant endophenotypes and the bootstrap total significance test for identifying genetic variation underlying the etiology of schizophrenia. In addition, the observation of extensive pleiotropy for some genes and singular associations for others suggests alternative, independent pathways mediating pathogenesis in the “group of schizophrenias.”

Abstract Teaser
Figures in this Article

Genetic factors clearly play a substantial role in the etiology of schizophrenia, as evidenced by family and twin studies that indicate a heritability of up to 80% for the disorder (1, 2). Although a number of replicated linkages have been reported, implicating multiple chromosomal regions (35), none of these linkage findings has led to cloning of causative genes for schizophrenia. Several neurobiologically plausible candidate genes have, however, been identified (6, 7).

An alternative to linkage and other agnostic analysis methods that may aid in the genetic dissection of complex diseases is interrogation of candidate genes thought to be associated with both the qualitative diagnostic category and quantitative endo- or intermediate phenotypes. This neurobiologically informed strategy utilizes existing knowledge of the underlying neural substrates of the disorder and may be particularly informative in unraveling the genetic architecture of schizophrenia. As part of the Consortium on the Genetics of Schizophrenia (COGS; 810), we constructed a custom single-nucleotide polymorphism (SNP) array containing 1,536 SNPs in 94 genes of relevance to schizophrenia and related phenotypes. We used information regarding putatively important neurobiological systems, as well as an extensive review of published linkage, association, and model organism studies, to identify and rank genes in terms of their level of importance in understanding schizophrenia. The resulting COGS SNP chip provides excellent coverage of many previously suggested candidate genes for schizophrenia, including AKT1, CHRNA7, COMT, DAO, DAOA, DISC1, DTNBP1, ERBB4, GRM3, GSK3B, NOS1AP, NRG1, PAFAH1B1, PPP3CC, PRODH, RELN, and RGS4 (6, 7), as well as several novel genes from putatively important pathways.

We utilized the COGS SNP chip to evaluate the associations of these 94 candidate genes with 12 heritable neurophysiological and neurocognitive endophenotypes that have been shown to be characteristically impaired in schizophrenia: prepulse inhibition of the startle response, P50 suppression, the antisaccade task for eye movements, continuous performance, letter-number span, verbal learning, abstraction and mental flexibility, face memory, spatial memory, spatial processing, sensorimotor dexterity, and emotion recognition. Our goal was not only to identify singular genetic associations with the COGS endophenotypes but also to assess the degree of pleiotropy (genetic associations with multiple endophenotypes). Since genes exhibiting pleiotropic effects across several endophenotypes may have far-reaching neurobehavioral implications, these genes may be optimal candidates to serve as biomarkers for early identification and intervention in schizophrenia in at-risk populations, as well as targets for treatment with novel pharmaceutical and psychosocial therapies. To confirm the collective significance of our findings, we also developed a novel multiple testing strategy, the bootstrap total significance test, which overcomes some of the limitations of similar methods currently used in genomics.

+

Family Ascertainment

Families were ascertained through the identification of probands at each of the seven COGS sites who met the DSM-IV-TR criteria for schizophrenia on the basis of administration of the Diagnostic Interview for Genetic Studies (11) and the Family Interview for Genetic Studies (12). The minimal requirement for pedigree ascertainment was a schizophrenia proband, both parents, and at least one unaffected sibling. This sampling strategy provides greater potential for phenotypic contrasts between and among the siblings for quantitative genetic analyses. Additional affected and unaffected siblings were collected whenever possible. The age range was set a priori at 18–65 years. All subjects received urine toxicology screens for drugs of abuse before phenotyping (negative screens were required). The ascertainment and screening procedures, inclusion and exclusion criteria, and descriptive statistics for the study group are discussed in detail elsewhere (10). After a detailed description of study participation, written informed consent was obtained for each subject in accordance with the protocols of the local institutional review boards.

+

Endophenotypes

Each subject in the study group was assessed for 12 endophenotypes, as described elsewhere in detail (13, 14), all of which have been shown to be heritable (15). Prepulse inhibition was measured as the percentage inhibition of the startle reflex in response to a weak prestimulus with a 60-msec interval from prepulse to startle stimulus (1618). P50 suppression was measured as the difference between the amplitudes of the P50 event-related potentials generated in response to conditioning and test stimuli presented with a 500-msec interstimulus interval (19, 20). Although the ratio is the more commonly used measure of P50 suppression, we have found the difference score to be more heritable in our COGS families (15). The “overlap” antisaccade task of oculomotor inhibition, which requires subjects to fixate on a central target and respond to a peripheral cue by looking in the opposite direction at the same distance, was measured as the ratio of correct antisaccades to total interpretable saccades (21, 22). The degraded stimulus version of the Continuous Performance Test (referred to later as “continuous performance”), a widely used measure of deficits in sustained, focused attention with a high perceptual load, was used to assess correct target detections and incorrect responses to nontargets (d′) (23 and 1999 software by K.H. Nuechterlein and R.F. Asarnow, version 8.11). The letter-number span, part of the Wechsler Memory Scale, is a prototypical task to assess storage of working memory information with manipulation; it requires the correct reordering of intermixed numbers and letters. For the assessment of verbal learning and memory, we used the California Verbal Learning Test (24) (“verbal learning”), an established list-learning test that provides a total score for recall of a list of 16 verbally presented items summed over five trials.

We also employed a modified version of the University of Pennsylvania Computerized Neurocognitive Battery (25, 26), excluding measures of attention and verbal and working memory, which were assessed as detailed in the preceding. Six measures were evaluated by using this battery. The test for abstraction and mental flexibility (“abstraction”) presents four objects from which the subject must choose the one that does not belong. An assessment of face memory requires subjects to recognize 20 previously presented target faces among 20 distracter faces. The assessment of spatial memory uses euclidean shapes as learning stimuli in a recognition paradigm identical to that used for face memory. For an assessment of spatial processing, two lines are presented at an angle, and the corresponding lines must be identified on a simultaneously presented array. The assessment of sensorimotor dexterity requires the subject to click with a mouse as quickly as possible on a target that gets increasingly smaller. The assessment of emotion recognition involves the correct identification of a variety of facial expressions of emotion. Each of these tests was measured as “efficiency,” calculated as accuracy/(log10 speed) and expressed as standard equivalents (z scores).

+

Custom SNP Chip

Genes of interest were identified and ranked in terms of their level of importance in understanding schizophrenia according to complementary information from a number of research domains: 1) linkage and association studies of schizophrenia and related phenotypes, 2) model organism, gene expression, and brain imaging studies, and 3) genetic networks and biological pathways relevant to schizophrenia. We mined public databases for general information about the genes and polymorphic variants of interest, including haplotype-tagging and potentially functional SNPs and those with previous reports of association with schizophrenia or related phenotypes. These data were then combined and compared to the list of SNPs available from Illumina, Inc. (San Diego, Calif.), for choice of the final 1,536 SNPs in 94 genes. A total of 1,417 haplotype-tagging SNPs obtained from the TAMAL web site (Technology And Money Are Limiting; 27) were selected from Caucasian HapMap populations (28) to efficiently interrogate 86 of the genes with an r2 threshold of 0.8 in our primarily (89%) Caucasian subjects. We included 5 kilobases (kb) of flanking sequence on either side of each gene to capture nearby regulatory elements in the tagged regions. The TAGGER SNP selection algorithm (29), with an aggressive tagging mode forcing all coding SNPs into the model, was used to select tagging SNPs for 76 of the genes. The SNP selection algorithm of Gabriel et al. (30) with a pairwise tagging mode was used to select tagging SNPs for an additional 10 genes to achieve sufficient gene coverage with the available SNPs. A combination of gene-spanning and putatively associated SNPs was used for the remaining eight genes because suitable tagging SNPs were not available. For CHRNA7, SNPs were selected within exons/introns 1–4 only, as the remainder of the gene cannot be screened because of a partial duplication, CHRFAM7A (31). The custom array includes 109 SNPs in 33 genes with reported evidence of association, 29 coding sequence variants in 17 genes (25 nonsynonymous and four synonymous), and 18 SNPs located in putative promoter regions or transcription factor binding sites. On average, there is one SNP per 10 kb for each gene with variance due to linkage disequilibrium patterns, SNP availability, etc. Minor allele frequencies for these SNPs ranged from 0.01 to 0.50, with an average of 0.23. The complete list of all 1,536 SNPs and 94 candidate genes included on the COGS SNP chip and the specific details from our research are available in Supplemental Table 1, which accompanies the online version of this article; this information includes RefSNP accession identification numbers (rs numbers), chromosomal locations, gene information, designation of SNPs (e.g., as tagging, coding, putatively functional, or associated, including p values and references), relevant sequence information, and minor allele frequencies for the four HapMap populations. Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, Calif.) was used to investigate the molecular interactions among the included genes and to provide information regarding pathway membership.

+

Study Group

A group of 534 subjects from 130 families was selected for genotyping on the basis of the availability of locally collected blood from five of the seven COGS sites. For each family, both endophenotype data and DNA were available for all schizophrenia probands and at least one unaffected sibling, for a total of 130 sibling pairs discordant for schizophrenia. DNA was also available for 217 parents, 130 of whom were phenotyped. An additional 73 phenotyped siblings were included across the family set as well, 57 of whom were also genotyped and six of whom had schizophrenia. On average, cleaned endophenotype data were available for 370 (SD=41) subjects. This study group has more than 80% power to detect SNPs explaining 3% of the variance at p<0.01, 4% of the variance at p<10–3, and 5.5% of the variance at p<10–4.

+

Genotyping and Cleaning

Genotyping was performed by the Biomedical Genomics Laboratory at the University of California, San Diego, by means of an Illumina BeadStation 500 scanner (Illumina, San Diego) and 20 μl of genomic DNA at 50 ng/μl plated on 96-well plates with three positive controls per plate. Genotype data were cleaned by using Illumina's BeadStudio software, version 3. Each subject was evaluated across all 1,536 SNPs, and six subjects were excluded for having poor allele call rates, defined as an average call rate below 80% and a median genotype call score below 0.76. Each SNP was then evaluated across all remaining subjects, and 38 SNPs were excluded for having average call rates below 90% and cluster separation scores below 0.05. Another 95 SNPs were eliminated after a manual examination of all SNPs with call rates above 90% but cluster separation scores between 0.05 and 0.25. A total of 133 SNPs were thus removed, resulting in a 91.3% SNP assay conversion rate. An additional 0.03% of the genotypes were removed because of Mendelian inconsistencies. The final group of 1,403 passing SNPs had a genotype call rate of 99.98% (749,052 genotypes called out of a possible 749,202). Accuracy estimated from 72 replicate DNA samples genotyped across the panel indicated a 99.98% reproducibility rate (100,139 identical genotypes out of a possible 100,163). Further quality control assessments using the PLINK analysis tool set (32) identified 15 SNPs with minor allele frequencies less than 0.01 in the unrelated individuals (i.e., parents) and three SNPs with Hardy-Weinberg equilibrium p values less than 10–4. Removal of these additional SNPs resulted in the final 1,385 SNPs with minor allele frequencies approximating those observed in the Caucasian HapMap sample.

+

Covariate Selection and Population Stratification

Multidimensional scaling, as implemented in PLINK, was used to assess the degree of population stratification in this study group and to validate the self-reported subject ancestries, which are not always reliable. These results suggested that subjects of Caucasian ancestry formed the largest and most genetically homogenous group, encompassing 89% of the subjects. Although the remaining subjects reported varying degrees of Hispanic, Native American, Asian, and African American ancestry, most generally clustered with the Caucasian group. To further evaluate the effects of the observed admixture, the first two principal components from the multidimensional scaling analysis were investigated as covariates, along with age and sex, through heritability analyses of the endophenotypes using SOLAR software (33). All factors found to be significant covariates were incorporated in the subsequent association analyses. Bivariate genetic correlations between endophenotypes were also explored. The heritability estimates and genetic correlations obtained in these analyses were similar to those we previously reported in a larger group that includes the current subjects (15), and those findings are not reiterated here. Schizophrenia was not included as a covariate in these analyses, since that would effectively remove the part of the gene-endophenotype association specifically related to schizophrenia. Therefore, the analysis could not reveal significant SNP associations with an endophenotype perfectly correlated with schizophrenia status, no matter the causal pathway between genotype and endophenotype.

+

Variance-Component Family Association Analyses

We employed the variance-component association module of the Merlin software package, version 1.1.2 (34), to assess the degree of association between the 1,385 SNPs and 12 endophenotypes in the 130 families. The association analyses were adjusted for age (all endophenotypes except P50 suppression), sex (prepulse inhibition, P50 suppression, verbal learning, spatial processing, emotion recognition), and ancestry as the first principal component from the multidimensional scaling analysis (antisaccade, continuous performance, verbal learning, spatial memory, spatial processing). A secondary analysis was also performed in Merlin to assess the independence of multiple associations by using the most significant SNP as a covariate, thereby decreasing the significance of any other SNPs in linkage disequilibrium with it. Independent signals were considered those remaining at p<0.01. For comparison purposes, the DFAM module of PLINK was used to perform an analysis of sibling pairs discordant for schizophrenia with the 1,361 autosomal SNPs. The effective number of independent SNPs tested, accounting for redundancies in linkage disequilibrium due to the inclusion of putatively functional and/or associated SNPS along with tagging SNPs and gene-spanning SNPs, was determined to be 977, with a corresponding Bonferroni correction for multiple comparisons of p=5×10–5 (35) for a given endophenotype and 4.2×10–6 for all 12 endophenotypes. The latter number is very conservative because of the observed between-endophenotype correlations, which complicate exact adjustment across endophenotypes. The multiple testing issue is further addressed by the total significance test, described in the following.

+

Total Significance Test for Multiple Tests

To test whether the observed genotype-endophenotype associations significantly exceed what would be seen by chance given that there are 16,620 total tests (1,385 SNPs and 12 endophenotypes), we developed and implemented a separate, novel multiple testing strategy, the bootstrap total significance test. Our strategy introduces two innovations that together overcome several limitations of existing genomic multiple testing methods.

First, we base our approach on bootstrap sampling instead of permutation sampling. The bootstrap works in settings where permutation tests cannot be applied or can be applied only with difficulty (36). Bootstrapping allows straightforward handling of family data even with complex patterns of missing data. In contrast, permutation procedures for family data are difficult to construct and do not use all information in the data if genetic variants drive phenotypic differences between families (36). Bootstrapping also handles confounding variables easily. Permutation tests do not, as the confounder is potentially associated with both predictor and outcome under the null hypothesis. Most important, this problem arises when covariates are included to adjust for cryptic population stratification. Bootstrapping will also work when the goal is to test an interaction in the presence of main effects.

Second, we introduce the concept of a total significance test to determine whether the strongest genotype-endophenotype associations are more extreme than expected by chance alone. The total significance test provides a rigorous statistical p value that collectively applies to the strongest results in the data but is less conservative than standard p value adjustments for multiple tests. This test is less dependent than other multiple testing methods on extremely small p values, which are difficult to obtain with moderate group sizes and may, even in large groups, be due more to rare sampling events or statistical flukes than to replicable biological findings. Last, we use the results of the bootstrap total significance test to provide an a posteriori predictive value for each genotype-endophenotype association, giving a measure of how likely each detected association is to be true. When the preceding factors are not present and bootstrapping is not required, the total significance test can also be based on permutation sampling.

We implemented the bootstrap total significance test in MatLab (MathWorks, Natick, Mass.). Specifically, we first applied a multiple regression model to the original data for each of the 1,385×12 SNP-endophenotype combinations, with the endophenotype as the dependent variable and the SNP (coded as the number of copies of the minor allele) and relevant covariates (those used in the variance-component Merlin analyses) as independent predictors. Thus, the multiple regression model used in the total significance test was identical to the variance-component model used in the Merlin analyses, with the sole exception of the within-family correlation structure. For each SNP-endophenotype combination in the original data, we calculated a z statistic, Z=(B–0)/s, where B is the estimated regression coefficient corresponding to the SNP and s is its estimated standard error (SE) in the multiple regression. The value 0 is the expected value of B under the null hypothesis of no SNP-endophenotype association.

We then simulated the same statistics under the null hypothesis by generating one group of 10,000 random bootstrap data sets (the training group) and a second group of 1,000 identically generated bootstrap data sets (the test group), following standard bootstrap theory for clustered data (37). To create each bootstrap data set, we randomly selected families from the original set of 130 families with replacement (i.e., families were selected randomly without respect to whether they were previously selected). Any one of the original families can appear multiple times in a single bootstrap data set or not at all. Each time a family appears, all data associated with it are placed in the new data set, including all family members, their covariates, endophenotypes, and genotypes. No data are rearranged, as they would be in a permutation test. For each bootstrap data set, z statistics were calculated as Z*=(B*–B)/s*, where B* and s* are the regression coefficient and SE calculated from the multiple regression applied to the bootstrap data. For a bootstrap sample, the true null hypothesis is given by the value estimated in the original data set, so that B replaces 0 in the formula for Z. The bootstrap Z* values provide an empirical estimate of the joint distribution of the Z values in the original data set, under the null hypothesis of no association. This is an application of standard bootstrap theory that is used, for example, in construction of the bootstrap-t confidence interval (37). The bootstrap automatically incorporates the empirically observed family-level correlation structure without relying on the assumption of a multivariate normal distribution, as well as inter-SNP correlations due to linkage disequilibrium.

To evaluate the p value for the total significance test, we then compared the test statistics for the original data to their bootstrap distributions. For each Z, we evaluated whether it was so extreme as to fall outside the range of Z* values for the same SNP-endophenotype combination in the 10,000 training bootstrap data sets. As each SNP-endophenotype combination is compared to its own distinct bootstrap distribution, an advantage of our approach is that there is no implicit assumption about exchangeability or identically distributed SNPs or endophenotypes. Let T0 be the total number of tested associations in the original data for which Z is either less than the minimum Z* or more than the maximum Z* in the 10,000 data set training group. Similarly, let T0* be the total number for each of the 1,000 independent bootstrap data sets in the test group, also based on comparison to the 10,000 data set training group. The collective p value for T0 is the proportion of bootstrap test data sets for which T0*≥T0. The question addressed by the total significance test is different from that for the “no family-wise error” criterion provided by a Bonferroni correction or a traditional permutation test. Thus, p values from the total significance test are not comparable to those provided by these other methods.

To obtain a posterior predictive value for the associations that were so significant as to be outside the range of the training group, we calculated the expected number of false positives F0 at this level as the averageT0* in the 1,000 training data sets. The posterior predictive value for all associations in this initial group was then calculated as (R0F0)/R0, where R0 is the number actually out of range in the original data.

We then extended this approach to determine if somewhat weaker results, those within the range of the tails of the bootstrap distribution, also significantly exceeded results expected by chance. Let T1 and T1* refer to totals based on comparison to the training group after the smallest and largest Z* values for each SNP-endophenotype combination are discarded. The subscript denotes the number discarded. A cumulative p value for T1 was calculated as the proportion of bootstrap data sets in the test group for which either T1*≥T1, T0*≥ T0, or both. T2, T3, and so on were computed, and a cumulative p value was calculated for each, with consideration of all prior tests of greater stringency. This p value simultaneously accounts for all stronger results and must increase sequentially. We considered all results satisfying a total cumulative, collective p value of ≤0.05 to be significant by the total significance and calculated posterior predictive values for each analogous to those described in the preceding.

+

Variance-Component Family Association Analyses

The results of the single-marker variance-component analyses implemented in Merlin, as shown in Figure 1 and detailed in the online Supplemental Table 2, revealed associations between the 12 endophenotypes and 46 of the 94 genes collectively. There were three SNPs having associations with p<10–4, 27 SNPs with p<10–3, and 147 SNPs with p<0.01, all of which may be of interest, given the a priori selection of these genes. There were 22 genes associated with at least one endophenotype at p<10–3, as indicated in Figure 1. The most significant finding in these analyses was the association of an SNP in NRG1 with spatial processing, which gave a p value of 6.4×10–6 and explained 6.9% of the genetic variation in this endophenotype. Two other SNPs gave p values less than 10–4, in GRIK4 (p=8.3×10–5) and CHRNA4 (p=9.0×10–5), explaining 5.4% and 4.5% of the genetic variation in antisaccade and sensorimotor dexterity, respectively. We also found evidence to support associations with four nonsynonymous SNPs and one synonymous SNP: GRM1 Gly884Glu (p=1.1×10–3 for verbal learning), NRG1 Arg38Gln (p=5.6×10–4 for verbal learning), SLC18A1 Val392Leu (p=9.7×10–3 for antisaccade), TAAR6 Val265Ile (p=1.1×10–3 for continuous performance), and HTR2A Ser34Ser (p=9.0×10–3 for letter-number span).

 
Anchor for JumpAnchor for Jump
FIGURE 1.

Analysis of Associations Between 1,385 Single-Nucleotide Polymorphisms (SNPs) in 94 Genes and 12 Endophenotypes for Schizophrenia in 130 Familiesa

a Each SNP-endophenotype association is represented by a dot and is color coded according to the endophenotype tested. The genes indicated down the right side of the figure are those having at least one SNP associated with one of the endophenotypes with p<10–3.

Figure 2 provides a summary of the minimum p value observed for each gene and endophenotype with the number of independent associations indicated, highlighting the associations of genes across endophenotypic domains. Although half of these genes were found to be associated (p<0.01) with two or more endophenotypes, eight genes in particular (CTNNA2, DISC1, ERBB4, GRID2, GRM1, NOS1AP, NRG1, and RELN) displayed extensive evidence for pleiotropy, revealing associations with four or more endophenotypes in this data set. In contrast, other genes (e.g., GRM3) were found to be associated with a single endophenotype (e.g., P50 suppression). Bivariate analyses revealed genetic correlations between continuous performance, abstraction, spatial processing, and emotion recognition that remained significant following correction for multiple testing (data presented elsewhere; 15). The genes that were generally associated with all of these four endophenotypes in the Merlin analyses were CTNNA2, GRM1, and RELN.

 
Anchor for JumpAnchor for Jump
FIGURE 2.

Most Significant Associations Between 46 Genes and 12 Endophenotypes for Schizophrenia in 130 Familiesa

a A minimum of p<0.01 was used as a threshold. Not all associations between a gene and the endophenotypes reflect associations with the same single-nucleotide polymorphism (SNP). Except for cells containing numbers, each gene had only one independent association, with no other SNP having p<0.01 after the most significant SNP was accounted for.

The COGS SNP chip includes a total of 40 genes that have shown prior allelic or haplotypic associations with schizophrenia or related endophenotypes. Specific SNPs for which evidence of association has been previously reported in the literature were included for 33 of these genes. Although associations with schizophrenia have also been reported for DRD2 (38), DRD4 (39), GRM4 (40), NRG1 (4145), PPP3CC (46), PRODH (47), and SLC1A2 (48), we were unable to include the specifically associated polymorphisms on this array because quality genotyping assays using this method were not available for these SNPs. The SNPs included on the array for 33 of the genes with prior evidence of association are presented in Table 1 with a comparison of associations in the previous and current studies. We have found evidence for association of 25 of the 40 previously associated genes (AKT1, CHRNA7, COMT, DAO, DISC1, DRD2, DRD3, ERBB4, GABRB2, GRID1, GRIK3, GRIK4, GRIN1, GRIN2B, GRM3, GRM4, HTR2A, NCAM1, NRG1, PRODH, SLC18A1, SLC1A2, SLC6A3, SP4, and TAAR6) with one or more endophenotypes, as detailed in Figure 2, including associations with 10 specific SNPs previously reported to be associated with schizophrenia (see Figure 2, Table 1, and online Supplemental Tables 1 and 2). The majority of the associations with specific SNPs (eight of 10) were in the same direction as in the previous studies. Although this study group was not recruited for an assessment of schizophrenia and is thus not well powered for this purpose, an analysis of discordant sibling pairs did indicate associations of SNPs within ERBB4, HTR4, and GRM5 with schizophrenia as well (p<0.01, data not presented). We did not find evidence for association of any endophenotype with ADRBK2, BDNF, CACNG2, DAOA, DGCR2, DRD4, DTNBP1, GAD1, HTR7, NEUROG1, NOTCH4, PPP1R1B, PPP3CC, RGS4, or ZDHHC8, despite previous reports of associations with schizophrenia.

 
Anchor for Jump
TABLE 1.

Single-Nucleotide Polymorphisms (SNPs) in 33 Genes Assayed in 130 Families and Associated With Schizophrenia or Related Phenotypes in Previous Studies

Table Footer Note

a Other associated SNPs in these genes were not included because quality genotyping assays using this method were not available for these SNPs.

Table Footer Note

b Effect was in the same direction as in the previous studies.

As shown in Figure 3, the genes included on the COGS SNP chip cluster into several putatively important pathways, including cell signal transduction, axonal guidance signaling, amino acid metabolism, and glutamate, serotonin, dopamine, and γ-aminobutyric acid (GABA) receptor signaling. The 46 genes found to be associated with at least one endophenotype were distributed among all of these pathways, with notably higher concentrations of associated genes observed in the glutamate signaling pathway. Of the 16 genes tested in the glutamate pathway, 14 revealed associations with at least one endophenotype, 10 of which were associated with two or more endophenotypes. Figure 4 further details the molecular interactions of a subset of the genes on the chip, highlighting the interactions between many of the 46 genes associated with at least one endophenotype. These data reveal a network of genes directly or indirectly related to glutamate signaling and suggest that disturbances of this pathway may contribute to schizophrenia susceptibility.

 
Anchor for JumpAnchor for Jump
FIGURE 3.

Distribution of 94 Candidate Genes for Schizophrenia in Known Biological Pathwaysa

a Distribution determined by Ingenuity Pathways Analysis (Ingenuity Systems, Redwood City, Calif.).

 
Anchor for JumpAnchor for Jump
FIGURE 4.

Path Diagram of Molecular Interactions Among 42 Candidate Genes for Schizophreniaa

a Genes are represented as nodes, and the biological relationship between two nodes is represented as a line or arrow supported by at least one reference from the literature, a textbook, or canonical information derived from the human, mouse, and rat orthologs of the gene that are stored in the Ingenuity Pathways Knowledge Base (Ingenuity Systems, Redwood City, Calif.).

+

Total Significance Test for Multiple Tests

Given that the association analyses involved 16,620 tests (1,385 SNPs and 12 endophenotypes), we expect some positive results due to chance. We therefore developed the bootstrap total significance test to evaluate whether there were more highly significant findings than would be expected by chance alone. Forty-seven of the z statistics in the original data were entirely outside the range observed in 10,000 bootstrap training data sets, simulated under the null hypothesis. The median number of such z statistics in the 1,000 test data sets was only two, and in 95% of the test data sets it was at most 12. Only one test data set yielded the 47 out-of-range z statistics seen in the observed data (p=0.001). These 47 findings have an estimated posterior predictive value of 93%.

We extended the total significance test sequentially to identify 292 SNP-endophenotype associations that collectively satisfied a cumulative p value of 0.05, discarding the 40 lowest and 40 highest bootstrap values for each test in each training data set. The corresponding posterior predictive value is 53%, indicating that each of these 292 findings more likely than not represents a true positive result. As a less stringent criterion is used and more values are trimmed from each end of the bootstrap training distribution, the posterior predictive value decreases (i.e., the corresponding results include more false positives) and results become less significant. The 292 most significant findings are summarized in Table 2 by gene, along with their significance in the separate variance-component analyses (see online Supplemental Table 3 for a complete list). Of the 94 genes on the array, 55 contained at least one SNP with an a posteriori chance of 53% or greater of being a true finding of association with at least one endophenotype. For the 12 endophenotypes, the number of significant findings ranged from 14 to 34. Negative results obtained through this approach should not be overinterpreted, since they are based only on the most significant associations in the data. Failure for a gene to have a test reaching this strict level of significance does not preclude the existence of more modest levels of association.

 
Anchor for Jump
TABLE 2.

Most Significant Findings in Bootstrap Total Significance Test Analysis of 1,385 Single-Nucleotide Polymorphism (SNPs) and 12 Endophenotypes for Schizophrenia

Table Footer Note

a Minimum p values in the variance-component analysis using Merlin software (34) are indicated with asterisks. All other genes shown had Merlin p values below 0.05. Merlin-associated genes SNAPAP, DRD3, and DAO were not significant in the bootstrap analyses.

Table Footer Note

*p<0.01. **p<10–3. ***p<10–4.

This study combined the analysis of 94 neurobiologically relevant genes and 12 heritable endophenotypes involving schizophrenia-related deficits (15), identifying an interesting pattern of association results for 46 genes across all endophenotypes. Given the observed correlations between many of these endophenotypes (15), we expect that some genes will exhibit pleiotropy and contribute to the variance in two or more endophenotypes. Additionally, some of the genes, such as NRG1, have been shown to play a role in neurodevelopment and therefore may affect more than one physiological or cognitive function. Even with the limited number of genes tested here, we do indeed find evidence of this pleiotropy. Of the eight genes revealing extensive evidence for pleiotropy across the 12 endophenotypes, six genes (ERBB4, GRID2, GRM1, NOS1AP, NRG1, and RELN) involved either directly or indirectly in glutamate signaling featured prominently with associations with five or more endophenotypes. We also observed association for 14 of 16 tested genes in the glutamate signaling pathway with at least one endophenotype, 10 of which were associated with two or more endophenotypes. These results are consistent with the glutamate hypothesis, which proposes that compromised N-methyl-d-aspartate (NMDA) receptor function contributes to the development of schizophrenia (117, 118), and the observation of a disproportionate disruption of genes in the neuregulin and glutamate pathways in schizophrenia patients (119). Collectively, these results support a strong role for genes involved in glutamate signaling in mediating schizophrenia susceptibility.

The associations of NRG1 and ERBB4 with five and eight endophenotypes, respectively, in this study add to the growing body of human molecular genetic studies implicating these genes, offering a compelling picture of the importance of neuregulin-mediated ErbB4 signaling in the pathophysiology of schizophrenia and its associated heritable deficits (83, 120122). The successful use of endophenotypes for schizophrenia in model organism studies provides additional support for the involvement of NRG1 in schizophrenia, as well as for this strategy of gene identification. For example, murine NRG1 hypomorphs show deficits in prepulse inhibition (120). Such deficits are well documented in schizophrenia patients (123126) and were found to be associated with NRG1 in our analyses. Neuregulin-1 is a trophic factor that signals through the activation of the ErbB receptor tyrosine kinases, such as ErbB4. ErbB4 plays a crucial role in neurodevelopment and in the modulation of NMDA receptor signaling, processes often disturbed in schizophrenia (127129). Neuregulin-mediated ErbB4 signaling has thus become an important pathway of consideration in schizophrenia research.

Custom SNP arrays, such as the COGS chip and the addiction array (130), have several advantages. They are affordable, are flexible with regard to the inclusion of desired variants, are focused by strong inference-based candidate gene selection to achieve disease specificity (for example, see reference 131), and may be much more feasible for use with smaller, yet well-defined, study groups that are underpowered for genome-wide association studies. Although more comprehensive, genome-wide arrays are nonspecific with regard to disease and may thus lack adequate representation of specific SNPs that have either been associated with or are thought to be of biological relevance to a particular disease. Some genes of interest, particularly smaller ones, may also be represented with insufficient coverage (e.g., SLC6A3) or not at all (e.g., DRD4) on genome-wide arrays. Large-scale analyses of candidate genes by means of custom arrays may therefore complement genome-wide association studies for investigators interested in specific genes and SNPs relevant to a particular disorder. This new array can serve as a publicly available resource for other investigators studying schizophrenia and related phenotypes, with the flexibility for modification of the SNP list to optimize it for the particular focus of the research group.

The novel bootstrap-based total significance test developed for this study demonstrates the overall significance of the COGS SNP chip and the associated endophenotypes. This total significance test goes beyond current multiple testing methods in order to provide a collective test of significance for the strongest results in an entire data set (or, if desired, over an individual gene or pathway), as well as to address situations where simple permutation schemes are not available, such as for family data and confounders that, by assumption, are associated with both genotype and phenotype (e.g., population stratification). Furthermore, it allows for the assignment of meaningful posterior predictive values to individual test results in the context of multiple testing. Limitations of the total significance test include its focus on the most significant test results, while ignoring the contribution of more modest association results. In addition, it was not practical, both in terms of software development and in terms of computer time, to embed the Merlin variance-component, pedigree-based analysis within the computationally complex total significance test. The bootstrap for clustered data (i.e., family data) is a well-validated statistical tool for obtaining accurate significance levels in this situation and is expected to correctly calibrate the statistical inferences for this limitation, but a total significance test that included within-family correlations in its statistical model might yield somewhat more efficient and powerful results than the present version.

Some caveats should be noted regarding this study. First, genetic analyses of schizophrenia are replete with failures to replicate previous findings (e.g., 132), despite the striking heritability of the disorder (2). Such failures are understandable in the context of ascertainment biases, population stratification, and cohort variance due to such factors as gender, smoking, treatment, and age at onset. Here, too, we have found no evidence for association with some prominent schizophrenia candidate genes, such as DAOA, DRD4, DTNBP1, PPP3CC, and RGS4 (6, 7). However, we have found further evidence to support association with 25 genes that have previously been reported to be associated with schizophrenia, including several specific SNPs for which the effect was in the same direction as in the previous study. Second, the family ascertainment scheme in this study focused on endophenotypes associated with schizophrenia and may thus be underpowered for detecting genetic variants associated with the disorder itself, and as might be expected for a heterogeneous disorder such as schizophrenia, not all individuals exhibit deficits across all of the endophenotypes studied. Additionally, antipsychotic medications may affect these results, although they tend to normalize endophenotypic scores, thus reducing, rather than increasing, the probability of significant associations. Although our study group was primarily (89%) of Caucasian ancestry, with most other subjects of partial Caucasian ancestry, we must also consider the possible confound of genetic admixture. We have used multidimensional scaling components as a measurement of ancestry to correct for this admixture in our analyses. We also note that allele frequencies from the Caucasian and African HapMap populations show an average difference of only 4% across our SNPs with p<0.01 and 6% across SNPs with p<10–3. Last, the degree of allelic, locus, and phenotypic heterogeneity associated with complex disorders now appears to be far more extensive than previously appreciated, with substantial contributions of rare de novo genetic variants, as well as epigenetic and environmental effects, none of which were assessed in this study (133).

Thus, we have observed many interesting associations between our endophenotypes and genes thought to be of biological relevance to schizophrenia. The extensive pleiotropy for some genes and singular associations for others in our data suggest alternative, independent pathways mediating schizophrenia pathogenesis. Further analyses of the genes associated with each of the endophenotypes will likely provide information regarding the underlying genetic pathways involved in schizophrenia susceptibility, as well as information regarding the interaction among these endophenotypes within the disorder. The illumination of the genetic basis of schizophrenia offers the exciting possibilities of early detection of the disorder and identification of novel pharmacologic targets to facilitate therapeutic intervention.

The authors thank all of the participants and support staff that made this study possible and Daniel R. Weinberger, M.D., for providing information on some of the included genes.

Owen  MJ;  O'Donovan  MC;  Gottesman  II:  Schizophrenia, in  Psychiatric Genetics and Genomics . Edited by McGuffin  P;  Owen  MJ;  Gottesman  II.  Oxford, UK,  Oxford University Press, 2002, pp 247–266
 
Sullivan  PF:  The genetics of schizophrenia.  PLoS Med 2005; 2(7):e212
[PubMed]
[CrossRef]
 
Baron  M:  Genetics of schizophrenia and the new millennium: progress and pitfalls.  Am J Hum Genet 2001; 68:299–312
[PubMed]
[CrossRef]
 
Lewis  CM;  Levinson  DF;  Wise  LH;  DeLisi  LE;  Straub  RE;  Hovatta  I;  Williams  NM;  Schwab  SG;  Pulver  AE;  Faraone  SV;  Brzustowicz  LM;  Kaufmann  CA;  Garver  DL;  Gurling  HM;  Lindholm  E;  Coon  H;  Moises  HW;  Byerley  W;  Shaw  SH;  Mesen  A;  Sherrington  R;  O'Neill  FA;  Walsh  D;  Kendler  KS;  Ekelund  J;  Paunio  T;  Lonnqvist  J;  Peltonen  L;  O'Donovan  MC;  Owen  MJ;  Wildenauer  DB;  Maier  W;  Nestadt  G;  Blouin  JL;  Antonarakis  SE;  Mowry  BJ;  Silverman  JM;  Crowe  RR;  Cloninger  CR;  Tsuang  MT;  Malaspina  D;  Harkavy-Friedman  JM;  Svrakic  DM;  Bassett  AS;  Holcomb  J;  Kalsi  G;  McQuillin  A;  Brynjolfson  J;  Sigmundsson  T;  Petursson  H;  Jazin  E;  Zoega  T;  Helgason  T:  Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia.  Am J Hum Genet 2003; 73:34–48
[PubMed]
[CrossRef]
 
Owen  MJ;  Williams  NM;  O'Donovan  MC:  The molecular genetics of schizophrenia: new findings promise new insights.  Mol Psychiatry 2004; 9:14–27
[PubMed]
[CrossRef]
 
Harrison  PJ;  Weinberger  DR:  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.  Mol Psychiatry 2005; 10:40–68
[PubMed]
[CrossRef]
 
Gogos  JA;  Gerber  DJ:  Schizophrenia susceptibility genes: emergence of positional candidates and future directions.  Trends Pharmacol Sci 2006; 27:226–233
[PubMed]
[CrossRef]
 
Braff  DL;  Freedman  R:  The importance of endophenotypes in studies of the genetics of schizophrenia, in  Neuropsychopharmacology: The Fifth Generation of Progress  . Edited by Davis  KL;  Charney  D;  Coyle  JT;  Nemeroff  C.  Baltimore,  Lippincott, Williams & Wilkins, 2002, pp 703–716
 
Braff  DL;  Freedman  R;  Schork  NJ;  Gottesman  II:  Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder.  Schizophr Bull 2007; 33:21–32
[PubMed]
[CrossRef]
 
Calkins  ME;  Dobie  DJ;  Cadenhead  KS;  Olincy  A;  Freedman  R;  Green  MF;  Greenwood  TA;  Gur  RE;  Gur  RC;  Light  GA;  Mintz  J;  Nuechterlein  KH;  Radant  AD;  Schork  NJ;  Seidman  LJ;  Siever  LJ;  Silverman  JM;  Stone  WS;  Swerdlow  NR;  Tsuang  DW;  Tsuang  MT;  Turetsky  BI;  Braff  DL:  The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration.  Schizophr Bull 2007; 33:33–48
[PubMed]
[CrossRef]
 
Nurnberger  JI  Jr;  Blehar  MC;  Kaufmann  CA;  York-Cooler  C;  Simpson  SG;  Harkavy-Friedman  J;  Severe  JB;  Malaspina  D;  Reich  T:  Diagnostic Interview for Genetic Studies: rationale, unique features, and training: NIMH Genetics Initiative.  Arch Gen Psychiatry 1994; 51:849–859; discussion, 863–864
[PubMed]
[CrossRef]
 
Faraone  SV;  Tsuang  D;  Tsuang  MT:  Genetics of Mental Disorders: A Guide for Students, Clinicians, and Researchers .  New York,  Guilford, 1999
 
Gur  RE;  Calkins  ME;  Gur  RC;  Horan  WP;  Nuechterlein  KH;  Seidman  LJ;  Stone  WS:  The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes.  Schizophr Bull 2007; 33:49–68
[PubMed]
[CrossRef]
 
Turetsky  BI;  Calkins  ME;  Light  GA;  Olincy  A;  Radant  AD;  Swerdlow  NR:  Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures.  Schizophr Bull 2007; 33:69–94
[PubMed]
[CrossRef]
 
Greenwood  TA;  Braff  DL;  Light  GA;  Cadenhead  KS;  Calkins  ME;  Dobie  DJ;  Freedman  R;  Green  MF;  Gur  RE;  Gur  RC;  Mintz  J;  Nuechterlein  KH;  Olincy  A;  Radant  AD;  Seidman  LJ;  Siever  LJ;  Silverman  JM;  Stone  WS;  Swerdlow  NR;  Tsuang  DW;  Tsuang  MT;  Turetsky  BI;  Schork  NJ:  Initial heritability analyses of endophenotypic measures for schizophrenia: the Consortium on the Genetics of Schizophrenia.  Arch Gen Psychiatry 2007; 64:1242–1250
[PubMed]
[CrossRef]
 
Braff  D;  Stone  C;  Callaway  E;  Geyer  M;  Glick  I;  Bali  L:  Prestimulus effects on human startle reflex in normals and schizophrenics.  Psychophysiology 1978; 15:339–343
[PubMed]
[CrossRef]
 
Braff  DL;  Geyer  MA;  Swerdlow  NR:  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.  Psychopharmacology (Berl) 2001; 156:234–258
[PubMed]
[CrossRef]
 
Swerdlow  NR;  Sprock  J;  Light  GA;  Cadenhead  K;  Calkins  ME;  Dobie  DJ;  Freedman  R;  Green  MF;  Greenwood  TA;  Gur  RE;  Mintz  J;  Olincy  A;  Nuechterlein  KH;  Radant  AD;  Schork  NJ;  Seidman  LJ;  Siever  LJ;  Silverman  JM;  Stone  WS;  Tsuang  DW;  Tsuang  MT;  Turetsky  BI;  Braff  DL:  Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia.  Schizophr Res 2007; 92:237–251
[PubMed]
[CrossRef]
 
Freedman  R;  Coon  H;  Myles-Worsley  M;  Orr-Urtreger  A;  Olincy  A;  Davis  A;  Polymeropoulos  M;  Holik  J;  Hopkins  J;  Hoff  M;  Rosenthal  J;  Waldo  MC;  Reimherr  F;  Wender  P;  Yaw  J;  Young  DA;  Breese  CR;  Adams  C;  Patterson  D;  Adler  LE;  Kruglyak  L;  Leonard  S;  Byerley  W:  Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus.  Proc Natl Acad Sci USA 1997; 94:587–592
[PubMed]
[CrossRef]
 
Olincy  A;  Braff  DL;  Adler  LE;  Cadenhead  KS;  Calkins  ME;  Dobie  DJ;  Green  MF;  Greenwood  TA;  Gur  RE;  Gur  RC;  Light  GA;  Mintz  J;  Nuechterlein  KH;  Radant  AD;  Schork  NJ;  Seidman  LJ;  Siever  LJ;  Silverman  JM;  Stone  WS;  Swerdlow  NR;  Tsuang  DW;  Tsuang  MT;  Turetsky  BI;  Wagner  BD;  Freedman  R:  Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the Consortium on Genetics of Schizophrenia.  Schizophr Res 2010; 119:175–182
[PubMed]
[CrossRef]
 
Radant  AD;  Dobie  DJ;  Calkins  ME;  Olincy  A;  Braff  DL;  Cadenhead  KS;  Freedman  R;  Green  MF;  Greenwood  TA;  Gur  RE;  Light  GA;  Meichle  SP;  Mintz  J;  Nuechterlein  KH;  Schork  NJ;  Seidman  LJ;  Siever  LJ;  Silverman  JM;  Stone  WS;  Swerdlow  NR;  Tsuang  MT;  Turetsky  BI;  Tsuang  DW:  Successful multi-site measurement of antisaccade performance deficits in schizophrenia.  Schizophr Res 2007; 89:320–329
[PubMed]
[CrossRef]
 
Radant  AD;  Dobie  DJ;  Calkins  ME;  Olincy  A;  Braff  DL;  Cadenhead  KS;  Freedman  R;  Green  MF;  Greenwood  TA;  Gur  RE;  Gur  RC;  Light  GA;  Meichle  SP;  Millard  SP;  Mintz  J;  Nuechterlein  KH;  Schork  NJ;  Seidman  LJ;  Siever  LJ;  Silverman  JM;  Stone  WS;  Swerdlow  NR;  Tsuang  MT;  Turetsky  BI;  Tsuang  DW:  Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: data from the COGS study.  Psychophysiology 2010; 47:846–856
[PubMed]
 
Nuechterlein  KH;  Parasuraman  R;  Jiang  Q:  Visual sustained attention: image degradation produces rapid sensitivity decrement over time.  Science 1983; 220:327–329
[PubMed]
[CrossRef]
 
Delis  D;  Kramer  J;  Kaplan  E;  Ober  B:  California Verbal Learning Test , 2nd ed.  San Antonio, Tex,  Psychological Corp, 2000
 
Gur  RC;  Ragland  JD;  Moberg  PJ;  Turner  TH;  Bilker  WB;  Kohler  C;  Siegel  SJ;  Gur  RE:  Computerized neurocognitive scanning, I: methodology and validation in healthy people.  Neuropsychopharmacology 2001; 25:766–776
[PubMed]
[CrossRef]
 
Gur  RC;  Ragland  JD;  Moberg  PJ;  Bilker  WB;  Kohler  C;  Siegel  SJ;  Gur  RE:  Computerized neurocognitive scanning, II: the profile of schizophrenia.  Neuropsychopharmacology 2001; 25:777–788
[PubMed]
[CrossRef]
 
Hemminger  BM;  Saelim  B;  Sullivan  PF:  TAMAL: an integrated approach to choosing SNPs for genetic studies of human complex traits.  Bioinformatics 2006; 22:626–627
[PubMed]
[CrossRef]
 
International HapMap Consortium:  A haplotype map of the human genome.  Nature 2005; 437:1299–1320
[PubMed]
[CrossRef]
 
de Bakker  PI;  Yelensky  R;  Pe'er  I;  Gabriel  SB;  Daly  MJ;  Altshuler  D:  Efficiency and power in genetic association studies.  Nat Genet 2005; 37:1217–1223
[PubMed]
[CrossRef]
 
Gabriel  SB;  Schaffner  SF;  Nguyen  H;  Moore  JM;  Roy  J;  Blumenstiel  B;  Higgins  J;  DeFelice  M;  Lochner  A;  Faggart  M;  Liu-Cordero  SN;  Rotimi  C;  Adeyemo  A;  Cooper  R;  Ward  R;  Lander  ES;  Daly  MJ;  Altshuler  D:  The structure of haplotype blocks in the human genome.  Science 2002; 296:2225–2229
[PubMed]
[CrossRef]
 
Gault  J;  Robinson  M;  Berger  R;  Drebing  C;  Logel  J;  Hopkins  J;  Moore  T;  Jacobs  S;  Meriwether  J;  Choi  MJ;  Kim  EJ;  Walton  K;  Buiting  K;  Davis  A;  Breese  C;  Freedman  R;  Leonard  S:  Genomic organization and partial duplication of the human alpha7 neuronal nicotinic acetylcholine receptor gene (CHRNA7).  Genomics 1998; 52:173–185
[PubMed]
[CrossRef]
 
Purcell  S;  Neale  B;  Todd-Brown  K;  Thomas  L;  Ferreira  MA;  Bender  D;  Maller  J;  Sklar  P;  de Bakker  PI;  Daly  MJ;  Sham  PC:  PLINK: a tool set for whole-genome association and population-based linkage analyses.  Am J Hum Genet 2007; 81:559–575
[PubMed]
[CrossRef]
 
Almasy  L;  Blangero  J:  Multipoint quantitative-trait linkage analysis in general pedigrees.  Am J Hum Genet 1998; 62:1198–1211
[PubMed]
[CrossRef]
 
Abecasis  GR;  Cherny  SS;  Cookson  WO;  Cardon  LR:  Merlin—rapid analysis of dense genetic maps using sparse gene flow trees.  Nat Genet 2002; 30:97–101
[PubMed]
[CrossRef]
 
Nyholt  DR:  A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other.  Am J Hum Genet 2004; 74:765–769
[PubMed]
[CrossRef]
 
Lazzeroni  LC;  Lange  K:  A conditional inference framework for extending the transmission/disequilibrium test.  Hum Hered 1998; 48:67–81
[PubMed]
[CrossRef]
 
Efron  B;  Tibshirani  RJ:  An Introduction to the Bootstrap .  New York,  Chapman & Hall, 1993
 
Kukreti  R;  Tripathi  S;  Bhatnagar  P;  Gupta  S;  Chauhan  C;  Kubendran  S;  Janardhan Reddy  YC;  Jain  S;  Brahmachari  SK:  Association of DRD2 gene variant with schizophrenia.  Neurosci Lett 2006; 392:68–71
[PubMed]
[CrossRef]
 
Nakajima  M;  Hattori  E;  Yamada  K;  Iwayama  Y;  Toyota  T;  Iwata  Y;  Tsuchiya  KJ;  Sugihara  G;  Hashimoto  K;  Watanabe  H;  Iyo  M;  Hoshika  A;  Yoshikawa  T:  Association and synergistic interaction between promoter variants of the DRD4 gene in Japanese schizophrenics.  J Hum Genet 2007; 52:86–91
[PubMed]
[CrossRef]
 
Fallin  MD;  Lasseter  VK;  Avramopoulos  D;  Nicodemus  KK;  Wolyniec  PS;  McGrath  JA;  Steel  G;  Nestadt  G;  Liang  KY;  Huganir  RL;  Valle  D;  Pulver  AE:  Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios.  Am J Hum Genet 2005; 77:918–936
[PubMed]
[CrossRef]
 
Stefansson  H;  Sarginson  J;  Kong  A;  Yates  P;  Steinthorsdottir  V;  Gudfinnsson  E;  Gunnarsdottir  S;  Walker  N;  Petursson  H;  Crombie  C;  Ingason  A;  Gulcher  JR;  Stefansson  K;  St Clair  D:  Association of neuregulin 1 with schizophrenia confirmed in a Scottish population.  Am J Hum Genet 2003; 72:83–87
[PubMed]
[CrossRef]
 
Hall  D;  Gogos  JA;  Karayiorgou  M:  The contribution of three strong candidate schizophrenia susceptibility genes in demographically distinct populations.  Genes Brain Behav 2004; 3:240–248
[PubMed]
[CrossRef]
 
Fukui  N;  Muratake  T;  Kaneko  N;  Amagane  H;  Someya  T:  Supportive evidence for neuregulin 1 as a susceptibility gene for schizophrenia in a Japanese population.  Neurosci Lett 2006; 396:117–120
[PubMed]
[CrossRef]
 
Li  D;  Collier  DA;  He  L:  Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia.  Hum Mol Genet 2006; 15:1995–2002
[PubMed]
[CrossRef]
 
Stefanis  NC;  Trikalinos  TA;  Avramopoulos  D;  Smyrnis  N;  Evdokimidis  I;  Ntzani  EE;  Ioannidis  JP;  Stefanis  CN:  Impact of schizophrenia candidate genes on schizotypy and cognitive endophenotypes at the population level.  Biol Psychiatry 2007; 62:784–792
[PubMed]
[CrossRef]
 
Liu  YL;  Fann  CS;  Liu  CM;  Chang  CC;  Yang  WC;  Hung  SI;  Yu  SL;  Hwang  TJ;  Hsieh  MH;  Liu  CC;  Tsuang  MM;  Wu  JY;  Jou  YS;  Faraone  SV;  Tsuang  MT;  Chen  WJ;  Hwu  HG:  More evidence supports the association of PPP3CC with schizophrenia.  Mol Psychiatry 2007; 12:966–974
[PubMed]
[CrossRef]
 
Li  T;  Ma  X;  Sham  PC;  Sun  X;  Hu  X;  Wang  Q;  Meng  H;  Deng  W;  Liu  X;  Murray  RM;  Collier  DA:  Evidence for association between novel polymorphisms in the PRODH gene and schizophrenia in a Chinese population.  Am J Med Genet B Neuropsychiatr Genet 2004; 129:13–15
[CrossRef]
 
Deng  X;  Shibata  H;  Ninomiya  H;  Tashiro  N;  Iwata  N;  Ozaki  N;  Fukumaki  Y:  Association study of polymorphisms in the excitatory amino acid transporter 2 gene (SLC1A2) with schizophrenia.  BMC Psychiatry 2004; 4:21 (http://www.biomedcentral.com/1471-244X/4/21)
[PubMed]
[CrossRef]
 
Barrett  TB;  Emberton  JE;  Nievergelt  CM;  Liang  SG;  Hauger  RL;  Eskin  E;  Schork  NJ;  Kelsoe  JR:  Further evidence for association of GRK3 to bipolar disorder suggests a second disease mutation.  Psychiatr Genet 2007; 17:315–322
[PubMed]
[CrossRef]
 
Schwab  SG;  Hoefgen  B;  Hanses  C;  Hassenbach  MB;  Albus  M;  Lerer  B;  Trixler  M;  Maier  W;  Wildenauer  DB:  Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families.  Biol Psychiatry 2005; 58:446–450
[PubMed]
[CrossRef]
 
Ikeda  M;  Iwata  N;  Suzuki  T;  Kitajima  T;  Yamanouchi  Y;  Kinoshita  Y;  Inada  T;  Ozaki  N:  Association of AKT1 with schizophrenia confirmed in a Japanese population.  Biol Psychiatry 2004; 56:698–700
[PubMed]
[CrossRef]
 
Bajestan  SN;  Sabouri  AH;  Nakamura  M;  Takashima  H;  Keikhaee  MR;  Behdani  F;  Fayyazi  MR;  Sargolzaee  MR;  Bajestan  MN;  Sabouri  Z;  Khayami  E;  Haghighi  S;  Hashemi  SB;  Eiraku  N;  Tufani  H;  Najmabadi  H;  Arimura  K;  Sano  A;  Osame  M:  Association of AKT1 haplotype with the risk of schizophrenia in Iranian population.  Am J Med Genet B Neuropsychiatr Genet 2006; 141:383–386
 
Neves-Pereira  M;  Cheung  JK;  Pasdar  A;  Zhang  F;  Breen  G;  Yates  P;  Sinclair  M;  Crombie  C;  Walker  N;  St Clair  DM:  BDNF gene is a risk factor for schizophrenia in a Scottish population.  Mol Psychiatry 2005; 10:208–212
[PubMed]
[CrossRef]
 
Liang  SG;  Shekhtman  T;  Gaucher  MA;  Barrett  TB;  Schork  NJ;  Berrettini  WH;  Byerley  W;  Coryell  W;  Gershon  ES;  McInnis  MG;  DePaulo  JR;  Nurnberger  JI;  Rice  JR;  Scheftner  W;  McMahon  FJ;  Kelsoe  JR:  High density SNP association study of 22q13 identifies CACGN2 as a susceptibility locus for bipolar disorder in two independent samples (abstract).  Am J Med Genet B Neuropsychiatr Genet 2005; 138B:27
 
Stephens  SH;  Logel  J;  Barton  A;  Franks  A;  Schultz  J;  Short  M;  Dickenson  J;  James  B;  Fingerlin  TE;  Wagner  B;  Hodgkinson  C;  Graw  S;  Ross  RG;  Freedman  R;  Leonard  S:  Association of the 5;-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia.  Schizophr Res 2009; 109:102–112
[PubMed]
[CrossRef]
 
Chen  X;  Wang  X;  O'Neill  AF;  Walsh  D;  Kendler  KS:  Variants in the catechol-o-methyltransferase (COMT) gene are associated with schizophrenia in Irish high-density families.  Mol Psychiatry 2004; 9:962–967
[PubMed]
[CrossRef]
 
Funke  B;  Malhotra  AK;  Finn  CT;  Plocik  AM;  Lake  SL;  Lencz  T;  DeRosse  P;  Kane  JM;  Kucherlapati  R:  COMT genetic variation confers risk for psychotic and affective disorders: a case control study.  Behav Brain Funct 2005; 1:19 (http://www.behavioralandbrainfunctions.com/content/1/1/19)
[PubMed]
[CrossRef]
 
Meyer-Lindenberg  A;  Nichols  T;  Callicott  JH;  Ding  J;  Kolachana  B;  Buckholtz  J;  Mattay  VS;  Egan  M;  Weinberger  DR:  Impact of complex genetic variation in COMT on human brain function.  Mol Psychiatry 2006; 11:867–877, 797
[PubMed]
[CrossRef]
 
Schurhoff  F;  Szoke  A;  Chevalier  F;  Roy  I;  Meary  A;  Bellivier  F;  Giros  B;  Leboyer  M:  Schizotypal dimensions: an intermediate phenotype associated with the COMT high activity allele.  Am J Med Genet B Neuropsychiatr Genet 2007; 144:64–68
 
Liu  X;  He  G;  Wang  X;  Chen  Q;  Qian  X;  Lin  W;  Li  D;  Gu  N;  Feng  G;  He  L:  Association of DAAO with schizophrenia in the Chinese population.  Neurosci Lett 2004; 369:228–233
[PubMed]
[CrossRef]
 
Schumacher  J;  Jamra  RA;  Freudenberg  J;  Becker  T;  Ohlraun  S;  Otte  AC;  Tullius  M;  Kovalenko  S;  Bogaert  AV;  Maier  W;  Rietschel  M;  Propping  P;  Nothen  MM;  Cichon  S:  Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder.  Mol Psychiatry 2004; 9:203–207
[PubMed]
[CrossRef]
 
Chumakov  I;  Blumenfeld  M;  Guerassimenko  O;  Cavarec  L;  Palicio  M;  Abderrahim  H;  Bougueleret  L;  Barry  C;  Tanaka  H;  La Rosa  P;  Puech  A;  Tahri  N;  Cohen-Akenine  A;  Delabrosse  S;  Lissarrague  S;  Picard  FP;  Maurice  K;  Essioux  L;  Millasseau  P;  Grel  P;  Debailleul  V;  Simon  AM;  Caterina  D;  Dufaure  I;  Malekzadeh  K;  Belova  M;  Luan  JJ;  Bouillot  M;  Sambucy  JL;  Primas  G;  Saumier  M;  Boubkiri  N;  Martin-Saumier  S;  Nasroune  M;  Peixoto  H;  Delaye  A;  Pinchot  V;  Bastucci  M;  Guillou  S;  Chevillon  M;  Sainz-Fuertes  R;  Meguenni  S;  Aurich-Costa  J;  Cherif  D;  Gimalac  A;  Van Duijn  C;  Gauvreau  D;  Ouellette  G;  Fortier  I;  Raelson  J;  Sherbatich  T;  Riazanskaia  N;  Rogaev  E;  Raeymaekers  P;  Aerssens  J;  Konings  F;  Luyten  W;  Macciardi  F;  Sham  PC;  Straub  RE;  Weinberger  DR;  Cohen  N;  Cohen  D:  Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia.  Proc Natl Acad Sci USA 2002; 99:13675–13680
[PubMed]
[CrossRef]
 
Hattori  E;  Liu  C;  Badner  JA;  Bonner  TI;  Christian  SL;  Maheshwari  M;  Detera-Wadleigh  SD;  Gibbs  RA;  Gershon  ES:  Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series.  Am J Hum Genet 2003; 72:1131–1140
[PubMed]
[CrossRef]
 
Addington  AM;  Gornick  M;  Sporn  AL;  Gogtay  N;  Greenstein  D;  Lenane  M;  Gochman  P;  Baker  N;  Balkissoon  R;  Vakkalanka  RK;  Weinberger  DR;  Straub  RE;  Rapoport  JL:  Polymorphisms in the 13q33.2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified.  Biol Psychiatry 2004; 55:976–980
[PubMed]
[CrossRef]
 
Ma  J;  Qin  W;  Wang  XY;  Guo  TW;  Bian  L;  Duan  SW;  Li  XW;  Zou  FG;  Fang  YR;  Fang  JX;  Feng  GY;  Gu  NF;  St Clair  D;  He  L:  Further evidence for the association between G72/G30 genes and schizophrenia in two ethnically distinct populations.  Mol Psychiatry 2006; 11:479–487
[PubMed]
[CrossRef]
 
Korostishevsky  M;  Kremer  I;  Kaganovich  M;  Cholostoy  A;  Murad  I;  Muhaheed  M;  Bannoura  I;  Rietschel  M;  Dobrusin  M;  Bening-Abu-Shach  U;  Belmaker  RH;  Maier  W;  Ebstein  RP;  Navon  R:  Transmission disequilibrium and haplotype analyses of the G72/G30 locus: suggestive linkage to schizophrenia in Palestinian Arabs living in the north of Israel.  Am J Med Genet B Neuropsychiatr Genet 2006; 141:91–95
 
Yue  W;  Kang  G;  Zhang  Y;  Qu  M;  Tang  F;  Han  Y;  Ruan  Y;  Lu  T;  Zhang  J;  Zhang  D:  Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects.  Neurosci Lett 2007; 416:96–100
[PubMed]
[CrossRef]
 
Shifman  S;  Levit  A;  Chen  ML;  Chen  CH;  Bronstein  M;  Weizman  A;  Yakir  B;  Navon  R;  Darvasi  A:  A complete genetic association scan of the 22q11 deletion region and functional evidence reveal an association between DGCR2 and schizophrenia.  Hum Genet 2006; 120:160–170
[PubMed]
[CrossRef]
 
Hennah  W;  Varilo  T;  Kestila  M;  Paunio  T;  Arajarvi  R;  Haukka  J;  Parker  A;  Martin  R;  Levitzky  S;  Partonen  T;  Meyer  J;  Lonnqvist  J;  Peltonen  L;  Ekelund  J:  Haplotype transmission analysis provides evidence of association for DISC1 to schizophrenia and suggests sex-dependent effects.  Hum Mol Genet 2003; 12:3151–3159
[PubMed]
[CrossRef]
 
Callicott  JH;  Straub  RE;  Pezawas  L;  Egan  MF;  Mattay  VS;  Hariri  AR;  Verchinski  BA;  Meyer-Lindenberg  A;  Balkissoon  R;  Kolachana  B;  Goldberg  TE;  Weinberger  DR:  Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia.  Proc Natl Acad Sci USA 2005; 102:8627–8632
[PubMed]
[CrossRef]
 
Liu  YL;  Fann  CS;  Liu  CM;  Chen  WJ;  Wu  JY;  Hung  SI;  Chen  CH;  Jou  YS;  Liu  SK;  Hwang  TJ;  Hsieh  MH;  Ouyang  WC;  Chan  HY;  Chen  JJ;  Yang  WC;  Lin  CY;  Lee  SF;  Hwu  HG:  A single nucleotide polymorphism fine mapping study of chromosome 1q42.1 reveals the vulnerability genes for schizophrenia, GNPAT and DISC1: association with impairment of sustained attention.  Biol Psychiatry 2006; 60:554–562
[PubMed]
[CrossRef]
 
Zhang  F;  Sarginson  J;  Crombie  C;  Walker  N;  St Clair  D;  Shaw  D:  Genetic association between schizophrenia and the DISC1 gene in the Scottish population.  Am J Med Genet B Neuropsychiatr Genet 2006; 141:155–159
 
Chen  QY;  Chen  Q;  Feng  GY;  Lindpaintner  K;  Wang  LJ;  Chen  ZX;  Gao  ZS;  Tang  JS;  Huang  G;  He  L:  Case-control association study of disrupted-in-schizophrenia-1 (DISC1) gene and schizophrenia in the Chinese population.  J Psychiatr Res 2007; 41:428–434
[PubMed]
[CrossRef]
 
Qu  M;  Tang  F;  Yue  W;  Ruan  Y;  Lu  T;  Liu  Z;  Zhang  H;  Han  Y;  Zhang  D;  Wang  F:  Positive association of the disrupted-in-schizophrenia-1 gene (DISC1) with schizophrenia in the Chinese Han population.  Am J Med Genet B Neuropsychiatr Genet 2007; 144:266–270
 
DeRosse  P;  Hodgkinson  CA;  Lencz  T;  Burdick  KE;  Kane  JM;  Goldman  D;  Malhotra  AK:  Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia.  Biol Psychiatry 2007; 61:1208–1210
[PubMed]
[CrossRef]
 
Talkowski  ME;  Seltman  H;  Bassett  AS;  Brzustowicz  LM;  Chen  X;  Chowdari  KV;  Collier  DA;  Cordeiro  Q;  Corvin  AP;  Deshpande  SN;  Egan  MF;  Gill  M;  Kendler  KS;  Kirov  G;  Heston  LL;  Levitt  P;  Lewis  DA;  Li  T;  Mirnics  K;  Morris  DW;  Norton  N;  O'Donovan  MC;  Owen  MJ;  Richard  C;  Semwal  P;  Sobell  JL;  St Clair  D;  Straub  RE;  Thelma  BK;  Vallada  H;  Weinberger  DR;  Williams  NM;  Wood  J;  Zhang  F;  Devlin  B;  Nimgaonkar  VL:  Evaluation of a susceptibility gene for schizophrenia: genotype based meta-analysis of RGS4 polymorphisms from thirteen independent samples.  Biol Psychiatry 2006; 60:152–162
[PubMed]
[CrossRef]
 
Dominguez  E;  Loza  MI;  Padin  F;  Gesteira  A;  Paz  E;  Paramo  M;  Brenlla  J;  Pumar  E;  Iglesias  F;  Cibeira  A;  Castro  M;  Caruncho  H;  Carracedo  A;  Costas  J:  Extensive linkage disequilibrium mapping at HTR2A and DRD3 for schizophrenia susceptibility genes in the Galician population.  Schizophr Res 2007; 90:123–129
[PubMed]
[CrossRef]
 
Straub  RE;  Jiang  Y;  MacLean  CJ;  Ma  Y;  Webb  BT;  Myakishev  MV;  Harris-Kerr  C;  Wormley  B;  Sadek  H;  Kadambi  B;  Cesare  AJ;  Gibberman  A;  Wang  X;  O'Neill  FA;  Walsh  D;  Kendler  KS:  Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia.  Am J Hum Genet 2002; 71:337–348
[PubMed]
[CrossRef]
 
Schwab  SG;  Knapp  M;  Mondabon  S;  Hallmayer  J;  Borrmann-Hassenbach  M;  Albus  M;  Lerer  B;  Rietschel  M;  Trixler  M;  Maier  W;  Wildenauer  DB:  Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families.  Am J Hum Genet 2003; 72:185–190
[PubMed]
[CrossRef]
 
van den Oord  EJ;  Sullivan  PF;  Jiang  Y;  Walsh  D;  O'Neill  FA;  Kendler  KS;  Riley  BP:  Identification of a high-risk haplotype for the dystrobrevin binding protein 1 (DTNBP1) gene in the Irish study of high-density schizophrenia families.  Mol Psychiatry 2003; 8:499–510
[PubMed]
[CrossRef]
 
Funke  B;  Finn  CT;  Plocik  AM;  Lake  S;  DeRosse  P;  Kane  JM;  Kucherlapati  R;  Malhotra  AK:  Association of the DTNBP1 locus with schizophrenia in a US population.  Am J Hum Genet 2004; 75:891–898
[PubMed]
[CrossRef]
 
Li  T;  Zhang  F;  Liu  X;  Sun  X;  Sham  PC;  Crombie  C;  Ma  X;  Wang  Q;  Meng  H;  Deng  W;  Yates  P;  Hu  X;  Walker  N;  Murray  RM;  St Clair  D;  Collier  DA:  Identifying potential risk haplotypes for schizophrenia at the DTNBP1 locus in Han Chinese and Scottish populations.  Mol Psychiatry 2005; 10:1037–1044
[PubMed]
[CrossRef]
 
Silberberg  G;  Darvasi  A;  Pinkas-Kramarski  R;  Navon  R:  The involvement of ErbB4 with schizophrenia: association and expression studies.  Am J Med Genet B Neuropsychiatr Genet 2006; 141:142–148
 
Lo  WS;  Lau  CF;  Xuan  Z;  Chan  CF;  Feng  GY;  He  L;  Cao  ZC;  Liu  H;  Luan  QM;  Xue  H:  Association of SNPs and haplotypes in GABAA receptor beta2 gene with schizophrenia.  Mol Psychiatry 2004; 9:603–608
[PubMed]
[CrossRef]
 
Lo  WS;  Harano  M;  Gawlik  M;  Yu  Z;  Chen  J;  Pun  FW;  Tong  KL;  Zhao  C;  Ng  SK;  Tsang  SY;  Uchimura  N;  Stober  G;  Xue  H:  GABRB2 association with schizophrenia: commonalities and differences between ethnic groups and clinical subtypes.  Biol Psychiatry 2007; 61:653–660
[PubMed]
[CrossRef]
 
Yu  Z;  Chen  J;  Shi  H;  Stoeber  G;  Tsang  SY;  Xue  H:  Analysis of GABRB2 association with schizophrenia in German population with DNA sequencing and one-label extension method for SNP genotyping.  Clin Biochem 2006; 39:210–218
[PubMed]
[CrossRef]
 
Addington  AM;  Gornick  M;  Duckworth  J;  Sporn  A;  Gogtay  N;  Bobb  A;  Greenstein  D;  Lenane  M;  Gochman  P;  Baker  N;  Balkissoon  R;  Vakkalanka  RK;  Weinberger  DR;  Rapoport  JL;  Straub  RE:  GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss.  Mol Psychiatry 2005; 10:581–588
[PubMed]
[CrossRef]
 
Shibata  H;  Aramaki  T;  Sakai  M;  Ninomiya  H;  Tashiro  N;  Iwata  N;  Ozaki  N;  Fukumaki  Y:  Association study of polymorphisms in the GluR7, KA1 and KA2 kainate receptor genes (GRIK3, GRIK4, GRIK5) with schizophrenia.  Psychiatry Res 2006; 141:39–51
[PubMed]
[CrossRef]
 
Pickard  BS;  Malloy  MP;  Christoforou  A;  Thomson  PA;  Evans  KL;  Morris  SW;  Hampson  M;  Porteous  DJ;  Blackwood  DH;  Muir  WJ:  Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder.  Mol Psychiatry 2006; 11:847–857
[PubMed]
[CrossRef]
 
Zhao  X;  Li  H;  Shi  Y;  Tang  R;  Chen  W;  Liu  J;  Feng  G;  Shi  J;  Yan  L;  Liu  H;  He  L:  Significant association between the genetic variations in the 5′ end of the N-methyl-D-aspartate receptor subunit gene GRIN1 and schizophrenia.  Biol Psychiatry 2006; 59:747–753
[PubMed]
[CrossRef]
 
Ohtsuki  T;  Sakurai  K;  Dou  H;  Toru  M;  Yamakawa-Kobayashi  K;  Arinami  T:  Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophrenia.  Mol Psychiatry 2001; 6:211–216
[PubMed]
[CrossRef]
 
Di Maria  E;  Gulli  R;  Begni  S;  De Luca  A;  Bignotti  S;  Pasini  A;  Bellone  E;  Pizzuti  A;  Dallapiccola  B;  Novelli  G;  Ajmar  F;  Gennarelli  M;  Mandich  P:  Variations in the NMDA receptor subunit 2B gene (GRIN2B) and schizophrenia: a case-control study.  Am J Med Genet B Neuropsychiatr Genet 2004; 128:27–29
[CrossRef]
 
Li  D;  He  L:  Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: a huge review and meta-analysis.  Genet Med 2007; 9:4–8
[PubMed]
[CrossRef]
 
Fujii  Y;  Shibata  H;  Kikuta  R;  Makino  C;  Tani  A;  Hirata  N;  Shibata  A;  Ninomiya  H;  Tashiro  N;  Fukumaki  Y:  Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia.  Psychiatr Genet 2003; 13:71–76
[PubMed]
 
Egan  MF;  Straub  RE;  Goldberg  TE;  Yakub  I;  Callicott  JH;  Hariri  AR;  Mattay  VS;  Bertolino  A;  Hyde  TM;  Shannon-Weickert  C;  Akil  M;  Crook  J;  Vakkalanka  RK;  Balkissoon  R;  Gibbs  RA;  Kleinman  JE;  Weinberger  DR:  Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.  Proc Natl Acad Sci USA 2004; 101:12604–12609
[PubMed]
[CrossRef]
 
Chen  Q;  He  G;  Wu  S;  Xu  Y;  Feng  G;  Li  Y;  Wang  L;  He  L:  A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population.  Schizophr Res 2005; 73:21–26
[PubMed]
[CrossRef]
 
Baritaki  S;  Rizos  E;  Zafiropoulos  A;  Soufla  G;  Katsafouros  K;  Gourvas  V;  Spandidos  DA:  Association between schizophrenia and DRD3 or HTR2 receptor gene variants.  Eur J Hum Genet 2004; 12:535–541
[PubMed]
[CrossRef]
 
Golimbet  VE;  Lavrushina  OM;  Kaleda  VG;  Abramova  LI;  Lezheiko  TV:  Supportive evidence for the association between the T102C 5-HTR2A gene polymorphism and schizophrenia: a large-scale case-control and family-based study.  Eur Psychiatry 2007; 22:167–170
[PubMed]
[CrossRef]
 
Ikeda  M;  Iwata  N;  Kitajima  T;  Suzuki  T;  Yamanouchi  Y;  Kinoshita  Y;  Ozaki  N:  Positive association of the serotonin 5-HT7 receptor gene with schizophrenia in a Japanese population.  Neuropsychopharmacology 2006; 31:866–871
[PubMed]
[CrossRef]
 
Sullivan  PF;  Keefe  RS;  Lange  LA;  Lange  EM;  Stroup  TS;  Lieberman  J;  Maness  PF:  NCAM1 and neurocognition in schizophrenia.  Biol Psychiatry 2007; 61:902–910
[PubMed]
[CrossRef]
 
Atz  ME;  Rollins  B;  Vawter  MP:  NCAM1 association study of bipolar disorder and schizophrenia: polymorphisms and alternatively spliced isoforms lead to similarities and differences.  Psychiatr Genet 2007; 17:55–67
[PubMed]
[CrossRef]
 
Fanous  AH;  Chen  X;  Wang  X;  Amdur  RL;  O'Neill  FA;  Walsh  D;  Kendler  KS:  Association between the 5q31.1 gene neurogenin1 and schizophrenia.  Am J Med Genet B Neuropsychiatr Genet 2007; 144:207–214
 
Zhang  X;  Wei  J;  Yu  YQ;  Liu  SZ;  Shi  JP;  Liu  LL;  Ju  GZ;  Yang  JZ;  Zhang  D;  Xu  Q;  Shen  Y;  Hemmings  GP:  Is NOTCH4 associated with schizophrenia? Psychiatr Genet 2004; 14:43–46
[PubMed]
[CrossRef]
 
Wang  Z;  Wei  J;  Zhang  X;  Guo  Y;  Xu  Q;  Liu  S;  Shi  J;  Yu  Y;  Ju  G;  Li  Y;  Shen  Y:  A review and re-evaluation of an association between the NOTCH4 locus and schizophrenia.  Am J Med Genet B Neuropsychiatr Genet 2006; 141:902–906
 
Meyer-Lindenberg  A;  Straub  RE;  Lipska  BK;  Verchinski  BA;  Goldberg  T;  Callicott  JH;  Egan  MF;  Huffaker  SS;  Mattay  VS;  Kolachana  B;  Kleinman  JE;  Weinberger  DR:  Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition.  J Clin Invest 2007; 117:672–682
[PubMed]
[CrossRef]
 
Chowdari  KV;  Mirnics  K;  Semwal  P;  Wood  J;  Lawrence  E;  Bhatia  T;  Deshpande  SN;  Thelma  BK;  Ferrell  RE;  Middleton  FA;  Devlin  B;  Levitt  P;  Lewis  DA;  Nimgaonkar  VL:  Association and linkage analyses of RGS4 polymorphisms in schizophrenia.  Hum Mol Genet 2002; 11:1373–1380
[PubMed]
[CrossRef]
 
Chen  X;  Dunham  C;  Kendler  S;  Wang  X;  O'Neill  FA;  Walsh  D;  Kendler  KS:  Regulator of G-protein signaling 4 (RGS4) gene is associated with schizophrenia in Irish high density families.  Am J Med Genet B Neuropsychiatr Genet 2004; 129:23–26
[CrossRef]
 
Morris  DW;  Rodgers  A;  McGhee  KA;  Schwaiger  S;  Scully  P;  Quinn  J;  Meagher  D;  Waddington  JL;  Gill  M;  Corvin  AP:  Confirming RGS4 as a susceptibility gene for schizophrenia.  Am J Med Genet B Neuropsychiatr Genet 2004; 125:50–53
[CrossRef]
 
Talkowski  ME;  Mansour  H;  Chowdari  KV;  Wood  J;  Butler  A;  Varma  PG;  Prasad  S;  Semwal  P;  Bhatia  T;  Deshpande  S;  Devlin  B;  Thelma  BK;  Nimgaonkar  VL:  Novel, replicated associations between dopamine D3 receptor gene polymorphisms and schizophrenia in two independent samples.  Biol Psychiatry 2006; 60:570–577
[PubMed]
[CrossRef]
 
Richards  M;  Iijima  Y;  Kondo  H;  Shizuno  T;  Hori  H;  Arima  K;  Saitoh  O;  Kunugi  H:  Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population.  Behav Brain Funct 2006; 2:39 (http://www.behavioralandbrainfunctions.com/content/2/1/39)
[PubMed]
[CrossRef]
 
Greenwood  TA;  Schork  NJ;  Eskin  E;  Kelsoe  JR:  Identification of additional variants within the human dopamine transporter gene provides further evidence for an association with bipolar disorder in two independent samples.  Mol Psychiatry 2006; 11:125–133
[PubMed]
[CrossRef]
 
Zhou  X;  Tang  W;  Greenwood  TA;  Guo  S;  He  L;  Geyer  MA;  Kelsoe  JR:  Transcription factor SP4 as a susceptibility gene for bipolar disorder.  PLoS One 2009; 4(4):e5196
[PubMed]
[CrossRef]
 
Duan  J;  Martinez  M;  Sanders  AR;  Hou  C;  Saitou  N;  Kitano  T;  Mowry  BJ;  Crowe  RR;  Silverman  JM;  Levinson  DF;  Gejman  PV:  Polymorphisms in the trace amine receptor 4 (TRAR4) gene on chromosome 6q23.2 are associated with susceptibility to schizophrenia.  Am J Hum Genet 2004; 75:624–638
[PubMed]
[CrossRef]
 
Pae  CU;  Yu  HS;  Amann  D;  Kim  JJ;  Lee  CU;  Lee  SJ;  Jun  TY;  Lee  C;  Paik  IH;  Patkar  AA;  Lerer  B:  Association of the trace amine associated receptor 6 (TAAR6) gene with schizophrenia and bipolar disorder in a Korean case control sample.  J Psychiatr Res 2008; 42:35–40
[PubMed]
[CrossRef]
 
Mukai  J;  Liu  H;  Burt  RA;  Swor  DE;  Lai  WS;  Karayiorgou  M;  Gogos  JA:  Evidence that the gene encoding ZDHHC8 contributes to the risk of schizophrenia.  Nat Genet 2004; 36:725–731
[PubMed]
[CrossRef]
 
Chen  WY;  Shi  YY;  Zheng  YL;  Zhao  XZ;  Zhang  GJ;  Chen  SQ;  Yang  PD;  He  L:  Case-control study and transmission disequilibrium test provide consistent evidence for association between schizophrenia and genetic variation in the 22q11 gene ZDHHC8.  Hum Mol Genet 2004; 13:2991–2995
[PubMed]
[CrossRef]
 
Coyle  JT:  Glutamate and schizophrenia: beyond the dopamine hypothesis.  Cell Mol Neurobiol 2006; 26:365–384
[PubMed]
[CrossRef]
 
Sodhi  M;  Wood  KH;  Meador-Woodruff  J:  Role of glutamate in schizophrenia: integrating excitatory avenues of research.  Expert Rev Neurother 2008; 8:1389–1406
[PubMed]
[CrossRef]
 
Walsh  T;  McClellan  JM;  McCarthy  SE;  Addington  AM;  Pierce  SB;  Cooper  GM;  Nord  AS;  Kusenda  M;  Malhotra  D;  Bhandari  A;  Stray  SM;  Rippey  CF;  Roccanova  P;  Makarov  V;  Lakshmi  B;  Findling  RL;  Sikich  L;  Stromberg  T;  Merriman  B;  Gogtay  N;  Butler  P;  Eckstrand  K;  Noory  L;  Gochman  P;  Long  R;  Chen  Z;  Davis  S;  Baker  C;  Eichler  EE;  Meltzer  PS;  Nelson  SF;  Singleton  AB;  Lee  MK;  Rapoport  JL;  King  MC;  Sebat  J:  Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia.  Science 2008; 320:539–543
[PubMed]
[CrossRef]
 
Stefansson  H;  Sigurdsson  E;  Steinthorsdottir  V;  Bjornsdottir  S;  Sigmundsson  T;  Ghosh  S;  Brynjolfsson  J;  Gunnarsdottir  S;  Ivarsson  O;  Chou  TT;  Hjaltason  O;  Birgisdottir  B;  Jonsson  H;  Gudnadottir  VG;  Gudmundsdottir  E;  Bjornsson  A;  Ingvarsson  B;  Ingason  A;  Sigfusson  S;  Hardardottir  H;  Harvey  RP;  Lai  D;  Zhou  M;  Brunner  D;  Mutel  V;  Gonzalo  A;  Lemke  G;  Sainz  J;  Johannesson  G;  Andresson  T;  Gudbjartsson  D;  Manolescu  A;  Frigge  ML;  Gurney  ME;  Kong  A;  Gulcher  JR;  Petursson  H;  Stefansson  K:  Neuregulin 1 and susceptibility to schizophrenia.  Am J Hum Genet 2002; 71:877–892
[PubMed]
[CrossRef]
 
Williams  NM;  Preece  A;  Spurlock  G;  Norton  N;  Williams  HJ;  Zammit  S;  O'Donovan  MC;  Owen  MJ:  Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia.  Mol Psychiatry 2003; 8:485–487
[PubMed]
[CrossRef]
 
Corvin  AP;  Morris  DW;  McGhee  K;  Schwaiger  S;  Scully  P;  Quinn  J;  Meagher  D;  Clair  DS;  Waddington  JL;  Gill  M:  Confirmation and refinement of an 'at-risk' haplotype for schizophrenia suggests the EST cluster, Hs 97362, as a potential susceptibility gene at the Neuregulin-1 locus.  Mol Psychiatry 2004; 9:208–213
[PubMed]
[CrossRef]
 
Braff  DL;  Greenwood  TA;  Swerdlow  NR;  Light  GA;  Schork  NJ:  Advances in endophenotyping schizophrenia.  World Psychiatry 2008; 7:11–18
[PubMed]
 
Parwani  A;  Duncan  EJ;  Bartlett  E;  Madonick  SH;  Efferen  TR;  Rajan  R;  Sanfilipo  M;  Chappell  PB;  Chakravorty  S;  Gonzenbach  S;  Ko  GN;  Rotrosen  JP:  Impaired prepulse inhibition of acoustic startle in schizophrenia.  Biol Psychiatry 2000; 47:662–669
[PubMed]
[CrossRef]
 
Kumari  V;  Sharma  T:  Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research.  Psychopharmacology (Berl) 2002; 162:97–101
[PubMed]
[CrossRef]
 
Duncan  EJ;  Szilagyi  S;  Efferen  TR;  Schwartz  MP;  Parwani  A;  Chakravorty  S;  Madonick  SH;  Kunzova  A;  Harmon  JW;  Angrist  B;  Gonzenbach  S;  Rotrosen  JP:  Effect of treatment status on prepulse inhibition of acoustic startle in schizophrenia.  Psychopharmacology (Berl) 2003; 167:63–71
[PubMed]
 
Ozaki  M;  Sasner  M;  Yano  R;  Lu  HS;  Buonanno  A:  Neuregulin-beta induces expression of an NMDA-receptor subunit.  Nature 1997; 390:691–694
[PubMed]
 
Rieff  HI;  Raetzman  LT;  Sapp  DW;  Yeh  HH;  Siegel  RE;  Corfas  G:  Neuregulin induces GABA(A) receptor subunit expression and neurite outgrowth in cerebellar granule cells.  J Neurosci 1999; 19:10757–10766
[PubMed]
 
Anton  ES;  Ghashghaei  HT;  Weber  JL;  McCann  C;  Fischer  TM;  Cheung  ID;  Gassmann  M;  Messing  A;  Klein  R;  Schwab  MH;  Lloyd  KC;  Lai  C:  Receptor tyrosine kinase ErbB4 modulates neuroblast migration and placement in the adult forebrain.  Nat Neurosci 2004; 7:1319–1328
[PubMed]
[CrossRef]
 
Hodgkinson  CA;  Yuan  Q;  Xu  K;  Shen  PH;  Heinz  E;  Lobos  EA;  Binder  EB;  Cubells  J;  Ehlers  CL;  Gelernter  J;  Mann  J;  Riley  B;  Roy  A;  Tabakoff  B;  Todd  RD;  Zhou  Z;  Goldman  D:  Addictions biology: haplotype-based analysis for 130 candidate genes on a single array.  Alcohol Alcohol 2008; 43:505–515
[PubMed]
 
Platt  JR:  Strong inference: certain systematic methods of scientific thinking may produce much more rapid progress than others.  Science 1964; 146:347–353
[PubMed]
[CrossRef]
 
Sanders  AR;  Duan  J;  Levinson  DF;  Shi  J;  He  D;  Hou  C;  Burrell  GJ;  Rice  JP;  Nertney  DA;  Olincy  A;  Rozic  P;  Vinogradov  S;  Buccola  NG;  Mowry  BJ;  Freedman  R;  Amin  F;  Black  DW;  Silverman  JM;  Byerley  WF;  Crowe  RR;  Cloninger  CR;  Martinez  M;  Gejman  PV:  No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics.  Am J Psychiatry 2008; 165:497–506
[PubMed]
[CrossRef]
 
McClellan  J;  King  MC:  Genetic heterogeneity in human disease.  Cell 2010; 141:210–217
[PubMed]
[CrossRef]
 
References Container

FIGURE 1. 

Analysis of Associations Between 1,385 Single-Nucleotide Polymorphisms (SNPs) in 94 Genes and 12 Endophenotypes for Schizophrenia in 130 Familiesa

a Each SNP-endophenotype association is represented by a dot and is color coded according to the endophenotype tested. The genes indicated down the right side of the figure are those having at least one SNP associated with one of the endophenotypes with p<10–3.

FIGURE 2. 

Most Significant Associations Between 46 Genes and 12 Endophenotypes for Schizophrenia in 130 Familiesa

a A minimum of p<0.01 was used as a threshold. Not all associations between a gene and the endophenotypes reflect associations with the same single-nucleotide polymorphism (SNP). Except for cells containing numbers, each gene had only one independent association, with no other SNP having p<0.01 after the most significant SNP was accounted for.

FIGURE 3. 

Distribution of 94 Candidate Genes for Schizophrenia in Known Biological Pathwaysa

a Distribution determined by Ingenuity Pathways Analysis (Ingenuity Systems, Redwood City, Calif.).

FIGURE 4. 

Path Diagram of Molecular Interactions Among 42 Candidate Genes for Schizophreniaa

a Genes are represented as nodes, and the biological relationship between two nodes is represented as a line or arrow supported by at least one reference from the literature, a textbook, or canonical information derived from the human, mouse, and rat orthologs of the gene that are stored in the Ingenuity Pathways Knowledge Base (Ingenuity Systems, Redwood City, Calif.).

Anchor for Jump
TABLE 1.

Single-Nucleotide Polymorphisms (SNPs) in 33 Genes Assayed in 130 Families and Associated With Schizophrenia or Related Phenotypes in Previous Studies

Table Footer Note

a Other associated SNPs in these genes were not included because quality genotyping assays using this method were not available for these SNPs.

Table Footer Note

b Effect was in the same direction as in the previous studies.